Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
Phase-I Open Label, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Chikungunya Vaccine in Healthy Adults of 18 to 50 Years Age
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Delhi, India
- Panchsheel Hospital
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, India
- King George Hospital
-
-
Haryana
-
Gurgaon, Haryana, India
- Medanta - The Medicity
-
-
Maharastra
-
Mumbai, Maharastra, India
- KEM Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥18 and ≤50 yrs inclusive on the day of screening
- Able and willing to complete informed consent process with understanding of the purpose and procedures of the study
- Medical history and physical examination without clinically significant findings at the time of screening
- Haematological and biochemical values either within institutional normal range and accompanied by physician approval
- Agree to keep a daily record of symptoms for the duration of the study
- Available for clinical follow-up throughout the study period via telephone contact as well as clinic visits
Female specific criteria:
- If female of child bearing potential- have a negative urine pregnancy test result within 24 hrs of the scheduled first vaccination
Exclusion Criteria:
Female specific criteria:
- Woman who is breast feeding or planning to become pregnant during the study period.
General Criteria:
- History of suspected or confirmed Chikungunya fever
(Case definition for Suspected Chikungunya: A subject meeting both the clinical and epidemiological criteria.
- Clinical criteria: acute onset of fever >38.5°C and severe arthralgia/arthritis not explained by other medical conditions.
- Epidemiological criteria: residing or having visited epidemic areas, having reported transmission within 15 days prior to the onset of symptoms.
Case definition for Confirmed Chikungunya:
A subject meeting the laboratory criteria of positive ELISA test for CHIKV IgG.)
- Clinically significant abnormal clinical laboratory values including blood pressure(>140 mmHg systolic and >90 mmHg diastolic) when 3 measurements are taken 30 min apart , in seating position and at rest
- Body mass index (BMI) ≥ 25 [BMI will be calculated as weight in Kilograms/(height in metres)2]
- Test positive for HIV or Hepatitis B infection
- History of cardiovascular disease
- History of immune deficiency or autoimmune disease
- Have active or history of arthritis (joint swelling, pain, tenderness, warmth or erythema) within the last 6 months from date of screening
- Have an active or history of malignant conditions including haematological malignancy
- Have a history of degenerative neurological disease (e.g. GuillainBarre Syndrome, multiple sclerosis)
- Have received any vaccination within 4 weeks prior to the vaccination in this study
- Have received blood transfusion or immunoglobulin within 30 days prior to vaccination in this study
- Have a history of serious reactions to any vaccines that preclude receipt of study vaccinations as determined by the investigator
- Have asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that is expected to require the use of oral or intravenous corticosteroids
- Have diabetes mellitus (type I or II), with the exception of history of gestational diabetes
- Have received any investigational drug in 6 weeks prior to screening
- Is currently participating in any form of clinical trial that involves intervention.
- Is likely to participate in any other clinical trial during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: BBV87 - 10 mcg
Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths (10, 20 and 30 mcg) administered intramuscularly on Day 0, 29 and 57
|
3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
|
|
PLACEBO_COMPARATOR: Placebo
Placebo administered intramuscularly on Day 0, 29 and 57
|
3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
|
|
EXPERIMENTAL: BBV87 -30 mcg
Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
|
3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
|
|
EXPERIMENTAL: BBV87 -20 mcg
Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
|
3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of adverse events and Serious Adverse events post each dose
Time Frame: Within 24 hrs
|
safety
|
Within 24 hrs
|
|
Occurrence of adverse events and Serious Adverse events post each dose
Time Frame: 7 Days,
|
safety
|
7 Days,
|
|
Occurrence of adverse events and Serious Adverse event 28 days after the last dose of vaccine
Time Frame: 9 months
|
safety
|
9 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immunogenicity in terms of GMT estimated by 50 percent plaque reduction neutralization test
Time Frame: day 28
|
Immunogenicity
|
day 28
|
|
Immunogenicity in terms of GMT estimated by 50 percent plaque reduction neutralization test
Time Frame: day 56
|
Immunogenicity
|
day 56
|
|
Immunogenicity in terms of GMT estimated by 50 percent plaque reduction neutralization test
Time Frame: day 84
|
Immunogenicity
|
day 84
|
|
Proportion of subjects with four fold seroconversion
Time Frame: day 28
|
Immunogenicity
|
day 28
|
|
Proportion of subjects with four fold seroconversion
Time Frame: day 56
|
Immunogenicity
|
day 56
|
|
Proportion of subjects with four fold seroconversion
Time Frame: day 84
|
Immunogenicity
|
day 84
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Krishna Mohan, PHD, Bharat Biotech International Limited
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BBIL/CHIKV/I/2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.